{'fraction_non_alphanumeric': 0.052795031055900624, 'fraction_numerical': 0.031055900621118012, 'mean_word_length': 4.47457627118644, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Aptamer therapy for SCD?

In this issue of Blood , Gutsaeva et al describe an aptamer with high affinity for murine P-selectin and its efficacy in preventing vaso-occlusion in a mouse sickle cell disease (SCD) model.[1][1]

Each year, more than 200 000 children are born with SCD,[2][2] yet there is a paucity of treatment